Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  lung cancer
Stage/Subtype:  lung cancer
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Trial Status:  Active
Results 1-25 of 41 for your search:
Start Over
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TG4010.14/TIME, 8559, NCT01383148
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NLG0301, 1209-1184, NCT01774578
Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KG 1/2012, NCT01579188
Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BV-NSCLC-002, 2013-005335-25, NCT02187367
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMS-NSCLC02, NCT00673777
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMS-NSCLC24, NCT00674258
Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0359-08-HMO-CTIL, NCT00722228
Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: sor469208ctil, NCT00828022
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16439, NCT01433172
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 6889, CNPq 577582/2008-9, NCT01584115
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2012-001852-20, NCT01789099
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: SUMS-23-56, NCT01949701
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: SUMS-23-57, 23-57, NCT01950156
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140053, 14-C-0053, NCT02054104
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I214, NCT02285816
Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18 to less than 80
Sponsor: Other
Protocol IDs: FudaCH, NCT02333474
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2727.00, NCI-2015-00329, P30CA015704, NCT02408016
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000632611, E6508, ECOG-E6508, NCT00828009
Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: IGR Dex2, NCT01159288
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UbiVac DPV-001, R44CA121612, NCT01909752
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Vx-001-201, NCT01935154
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HS110-201, NCT02117024
Vaccination of Stage IV NSCLC Patients With a Carbohydrate Mimotope Vaccine
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 203199, NCT02264236
Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 20
Sponsor: Other
Protocol IDs: IMS2643, UMIN000016979, NCT02410369
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCL5001-01, NCT00062907
Start Over